LabCoP session (ASLM): Surveillance of histidine-rich protein genes deletion in Plasmodium falciparum (Pfhrp2/3)

Surveillance of histidine-rich protein genes deletion in Plasmodium falciparum (PFHRP2/3)

Globally, malaria remains a pressing health concern, with an estimated 249 million cases and 608,000 deaths reported in 2022 alone. Africa bears a disproportionately high malaria burden, emphasising the critical need for timely and accurate malaria testing strategies and other control measures. Histidine-rich protein 2 (HRP2)-based rapid diagnostic tests (RDTs) have long been pivotal in malaria control efforts, particularly in sub-Saharan Africa. However, emerging deletions in the pfhrp2 and related pfhrp3 genes pose a significant threat to the efficacy of these tests.

In this session, The team delved into the latest WHO guidance on gene deletion surveillance, tools used and results from surveys done in Uganda and Ethiopia, and insights crucial for navigating this evolving landscape.

Presenters:

• Dr Xavier Ding, Global Clinical Strategy Manager, Abbott Diagnostics
• Dr Agaba Bosco, Malaria Diagnostics Coordinator, National Malaria Control Program, Ministry of Health, Uganda
• Mr Bokretsion Gidey Brhane, Team Leader Malaria and Parasitic Disease Research Team, EPHI